Premium
Assessment of drugs in schizophrenia. Basic trial design.
Author(s) -
Lader M
Publication year - 1976
Publication title -
british journal of clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.216
H-Index - 146
eISSN - 1365-2125
pISSN - 0306-5251
DOI - 10.1111/j.1365-2125.1976.tb03728.x
Subject(s) - clinical trial , schizophrenia (object oriented programming) , medicine , pharmacodynamics , drug , intensive care medicine , pharmacology , selection (genetic algorithm) , pharmacokinetics , psychiatry , computer science , machine learning
Clinical trials with major tranquilizers must take into account the clinical features of patients with schizophrenia and pharmacokinetic and pharmacodynamic properties of the drug. The objectives of the trial must be carefully defined so that appropriate selection criteria for patients, rating instruments and dosage schedules can be selected. It is useful to monitor physiological and biochemical actions of major tranquilizers as well as the clinical effects.